NCT05872256

A Demonstration of the Hair and Scalp Benefits of Duobrii in Scalp Psoriasis

A Demonstration of the Hair and Scalp Benefits of 0.045% Tazarotene/0.01% Halobetasol Lotion in Scalp Psoriasis

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: Dermatology Consulting Services, PLLC · Network
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The objectives of this research are to demonstrate the following:1. To demonstrate improvement in hair growth and hair appearance following 12 weeks of once daily treatment with tazarotene/halobetasol lotion in patients with moderate to severe scalp psoriasis.2. To demonstrate improvement in scalp itch reduction following 12 weeks of once daily treatment with tazarotene/halobetasol lotion in patients with moderate to severe scalp psoriasis.3. To pictorially demonstrate improvement in moderate to severe scalp psoriasis with 12 weeks of once daily treatment with tazarotene/halobetasol lotion.4. To assessment patient perceptions of the value of a lotion in the treatment of moderate to severe scalp psoriasis.

Detailed description

Male or female subjects with moderate to severe scalp psoriasis will present to the research center for evaluation for study entry. They will have been advised to present to the research center with clean hair and no topical products applied to the scalp. If found to be suitable by meeting all inclusion criteria and none of the exclusion criteria, subjects will undergo scalp psoriasis evaluation by the dermatologist investigator for erythema, scaling, and induration. The subjects will also assess each plaque for redness, thickness, and scaling. The subjects and the dermatologist will assess the hair for lack of hair shine, poor manageability, frizziness, poor hair color, poor hair growth, and damaged cuticle structure. The subjects will assess scalp itch. Finally, digital photography will be conducted of the scalp psoriasis.Each subject will be dispensed one tube of tazarotene/halobetasol lotion for application to scalp once daily. Subjects will be provided with a diary. Subjects will be instructed to return to the research center in 4 weeks. A reminder text for compliance will be provided prior to the week 4 visit and for all return visits.Subjects will return to the research center at week 4 and week 8 and week 12 for the same assessments. At week 12, a consumer perception survey will also be administered. All diaries will be collected at week 12. Subjects will be allowed to keep any unused study product. Subjects will complete their study participation at week 12.

Conditions

• Scalp Psoriasis

Interventions

Type	Name	Description
DRUG	0.045% Tazarotene/0.01% Halobetasol Lotion	FDA approved drug for psoriasis treatment

Timeline

• Start date: 2023-06-01
• Primary completion: 2023-11-13
• Completion: 2023-11-13
• First posted: 2023-05-24
• Last updated: 2023-11-18

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study